| Literature DB >> 28959580 |
Abstract
Septilin (Spt) is a polyherbal drug formulation from Himalaya Drug Company, consisting of extracts from different medicinal plants and minerals. In the traditional system of medicine, septilin is being used as immunomodulatory, antioxidant and anti-inflammatory agent. In the present study, the protective effects of septilin against the genotoxicity of cyclophosphamide (CP) a widely used alkylating anticancer drug was evaluated by using in vivo micronucleus (MN) and sperm shape abnormality assays in Swiss albino mice. CP administered intraperitoneally at a dose of 50 mg/kg b.w. was used as positive mutagen. Different doses of septilin viz., 125, 250 and 500 mg/kg b.w. was orally administered for 5 consecutive days. CP was administered intraperitoneally on 5th day. MN and sperm preparations were made after 24 h and 35 days respectively. CP induced significant MN in both bone marrow and peripheral blood cells and also a high frequency of abnormal sperms. In septilin supplemented animals, no significant induction of MN and abnormal sperms was recorded. In septilin supplemented groups, a dose dependent significant decrease in CP induced clastogenicity was observed. Thus the current in vivo study revealed the antigenotoxic effects of septilin against CP induced damage, in both somatic and germ cells of Swiss albino mice.Entities:
Keywords: A, amorphous; Antigenotoxic; B, banana shaped; BSA, bovine serum albumin; CMC, carboxymethyl cellulose; CP, cyclophosphamide; Cyclophosphamide; DH, double headed; DT, double tailed; F, folded; H, hookless; MN, micronucleus; MNNCE, micronucleus in normochromatic erythrocytes; MNPCE, micronucleus in polychromatic erythrocytes; Micronucleus test; NCE, normochromatic erythrocytes; PCE, polychromatic erythrocytes; Septilin; Sperm abnormality; Spt, septilin
Year: 2016 PMID: 28959580 PMCID: PMC5615931 DOI: 10.1016/j.toxrep.2016.07.001
Source DB: PubMed Journal: Toxicol Rep ISSN: 2214-7500
Frequency of micronucleus and total MN in bone marrow cells of animals treated with different doses of septilin and CP and their respective controls at 24 h time interval.
| Treatment mg/kg | MNPCE ± SEM (%) | % inhibition | Total MN ± SEM (%) | % inhibition | P/N ± SEM |
|---|---|---|---|---|---|
| Dist. Water | 0.09 ± 0.02 | – | 0.05 ± 0.02 | – | 1.10 ± 0.02 |
| CMC 0.5% | 0.10± 0.01 | – | 0.06 ± 0.01 | – | 1.10 ± 0.02 |
| Spt 125 | 0.04 ± 0.02 | – | 0.02 ± 0.02 | – | 1.16 ± 0.02 |
| Spt 250 | 0.01 ± 0.01 | – | 0.01 ± 0.01 | – | 1.30 ± 0.02 |
| Spt 500 | 0.01 ± 0.01 | – | 0.01 ± 0.01 | – | 1.22 ± 0.02 |
| CP50 | 2.20 ± 0.02c | – | 1.66 ± 0.02c | – | 0.58 ± 0.01c |
| CMC+ CP50 | 2.12 ± 0.05 | 3.64 ± 0.02 | 1.59 ± 0.02 | 4.22 ±0.01 | 0.59 ± 0.00 |
| Spt 125+ CP50 | 1.18 ± 0.05c | 46.4 ± 0.02c | 0.79 ± 0.06c | 52.4 ±0.02c | 0.85 ± 0.01c |
| Spt 250 + CP 50 | 0.32 ± 0.05c | 85.5 ±0.01c | 0.17 ± 0.02c | 89.8 ±0.01c | 0.91 ± 0.02c |
| Spt 500 + CP 50 | 0.70 ± 0.07c | 68.2 ±0.03c | 0.37 ± 0.01c | 77.7 ±0.03c | 0.87 ± 0.02c |
ANOVA test, ap < 0.05, b p < 0.01, cp < 0.001.
Results of peripheral blood MN test in animals treated with different doses of septilin and CP and their respective controls at 24 h time interval.
| Treatment mg/kg | Mean%NCE | Mean% PCE | Mean% of MN in NCE ± SEM | % Inhibition |
|---|---|---|---|---|
| Dist. Water | 98.1 ± 0.10 | 1.90 ± 0.09 | 0.05 ± 0.05 | – |
| CMC 0.5% | 98.0 ± 0.07 | 2.00 ± 0.09 | 0.03 ± 0.01 | – |
| Spt 125 | 97.6 ± 0.06 | 2.40 ± 0.03 | 0.02 ± 0.01 | – |
| Spt 250 | 97.8 ± 0.01 | 2.20 ± 0.09 | 0.02 ± 0.01 | – |
| Spt 500 | 97.8 ± 0.10 | 2.20 ± 0.01 | 0.02 ± 0.01 | – |
| CP50 | 98.9 ± 0.02 | 1.10 ± 0.03c | 0.53 ± 0.03c | – |
| CMC+ CP50 | 98.8 ± 0.02 | 1.20 ± 0.03 | 0.49 ± 0.02 | 7.50 ± 0.03 |
| Spt 125 + CP50 | 98.8 ± 0.02 | 1.30 ± 0.04a | 0.28 ± 0.03c | 47.2 ± 0.03c |
| Spt 250 + CP50 | 98.3 ± 0.09 | 1.70 ± 0.10c | 0.09 ± 0.02c | 83.0 ± 0.04a |
| Spt 500 + CP50 | 98.7 ± 0.04 | 1.50 ± 0.03b | 0.18 ± 0.03c | 66.0 ± 0.06c |
ANOVA test: ap<0.05, bp < 0.01, cp < 0.001.
Fig. 1Effect of septilin on MN PCE and Total MN induced by CP. ANOVA test, *p < 0.05, **p < 0.01, *** p < 0.001.
Fig. 3Effect of septilin on MN NCE induced by CP. ANOVA test, *p < 0.05, **p < 0.01, *** p < 0.001.
Fig. 5Effect of septilin on% of PCE in peripheral blood with CP alone and with combination of septilin. ANOVA test, *p < 0.05, **p < 0.01, *** p < 0.001.
Fig. 2% inhibition of CP induced MN by septilin. ANOVA test, *p < 0.05, **p < 0.01, ***p < 0.001.
Fig. 4% inhibition of MN NCE in peripheral blood by septilin in combined treatment. ANOVA test, *p < 0.05, **p < 0.01, *** p < 0.001.
Different types and total abnormal sperms induced by CP (50 mg/kg b.w.) and the ameliorating effect of septilin (5 weeks post treatment period).
| Treatment | A | H | F | B | DH | DT | Total | % Abnormal sperms ± SEM |
|---|---|---|---|---|---|---|---|---|
| Dist. Water | 76 | 44 | 2 | 0. | 0 | 0 | 122 | 1.22 ± 0.05 |
| CMC 0.5% | 76 | 43 | 2 | 0 | 0 | 0 | 121 | 1.21 ± 0.05 |
| Spt 125 | 55 | 48 | 0 | 0 | 0 | 0 | 103 | 1.03 ± 0.04 |
| Spt 250 | 28 | 15 | 0 | 0 | 0 | 0 | 43 | 0.43 ± 0.03 |
| Spt 500 | 41 | 17 | 0 | 0 | 0 | 0 | 58 | 0.58 ± 0.03 |
| CP50 | 250 | 136 | 88 | 38 | 28 | 23 | 563 | 5.63 ± 0.24 |
| CMC+ CP50 | 247 | 135 | 87 | 36 | 25 | 20 | 550 | 5.50 ± 0.22 |
| Spt 125 + CP50 | 189 | 130 | 71 | 30 | 07 | 08 | 435 | 4.35 ± 0.03c |
| Spt 250 + CP 50 | 76 | 46 | 53 | 16 | 04 | 04 | 199 | 1.99 ± 0.20c |
| Spt 500 + CP 50 | 87 | 58 | 50 | 25 | 07 | 05 | 232 | 2.32 ± 0.03c |
A—Amorphous; H—hookless; F—folded; B—Banana shaped; DH—Double Headed; DT—Double Tailed.
Five animals in each group; 2000 sperms/animal; ANOVA test, ap < 0.05, bp < 0.01, cp < 0.001.
Effect of different doses of septilin and controls on body weight, testes weight and sperm count in mice.
| Treatment | Initial b.w(gms) | Final b.w(gms) | Testes wt. (gms) ± SEM | Relative wt. of testes ± SEM | Sperm count/epididymis (×106) ± SEM |
|---|---|---|---|---|---|
| Dist. Water | 27.91 | 32.88 | 0.31 ± 0.01 | 0.94 ± 0.01 | 7.95 ± 0.15 |
| CMC 0.5% | 27.33 | 32.13 | 0.32 ± 0.02 | 0.99 ± 0.01 | 7.75 ± 0.42 |
| Spt 125 | 26.14 | 31.60 | 0.32 ± 0.02 | 1.01 ± 0.01 | 8.00 ± 0.23 |
| Spt 250 | 26.94 | 32.08 | 0.33 ± 0.04 | 1.03 ± 0.02 | 8.63 ± 0.23 |
| Spt 500 | 26.78 | 31.22 | 0.32 ± 0.02 | 1.02 ± 0.01 | 8.13 ± 0.40 |
| CP50 | 25.46 | 29.58 | 0.24 ± 0.01 | 0.81 ± 0.03 | 5.25 ± 0.38 |
| CMC+ CP50 | 26.66 | 30.94 | 0.24 ± 0.01 | 0.78 ± 0.03 | 5.38 ± 0.40 |
| Spt 125+ CP50 | 23.78 | 28.48 | 0.25 ± 0.02a | 0.88 ± 0.06a | 6.75 ± 0.23c |
| Spt 250 + CP 50 | 25.44 | 30.12 | 0.33 ± 0.01a | 1.10 ± 0.03a | 8.00 ± 0.23c |
| Spt 500 + CP 50 | 27.68 | 31.80 | 0.32 ± 0.01a | 1.00 ± 0.03a | 7.70 ± 0.15c |
Five animals in each group, ANOVA test, ap < 0.05, b p < 0.01, c p < 0.001.
Fig. 6Effect of septilin on sperm count with CP alone and with combination of septilin. ANOVA test, *p < 0.05, **p < 0.01, *** p < 0.001.